In the time since we last gathered for the International Congress on Hematologic Malignancies®, we’ve seen dozens of new or expanded approvals in hematology. The strides we have made in 2018 and the exciting developments and expectations for 2019 make me proud to be a hematologist oncologist and equally excited to invite you to participate in this year’s conference.
Beyond the expanding data on game changing CAR T-cell therapy, every field this year has seen profound changes: acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), peripheral T-cell lymphoma (PTCL), but also Waldenström macroglobulinemia and hairy cell leukemia!
Together with the leading experts we will discuss and review how these changes impact the way we manage our patients’ care.
Andrew H. Goy, MD, MS